Health Service Executive Statement of Revenue Income and Expenditure For the year ended 31 December 2021

Income			Notes	2021 €'000	202 €'00
	Departme	nt of Health Revenue Grant	3(a)	20,617,795	19,451,54
	Surplus/D	eficit on Revenue Income and Expenditure brought forward	3(b)		6,47
				20,617,795	19,458,01
	Patient Ind	come	4	342,780	328,54
	Other Inco	ome	5	486,904	478,17
				21,447,479	20,264,74
Expenditure					
	Pay and P	ensions			
		Clinical	6 & 7	4,390,573	4,127,29
		Non Clinical	6 & 7	1,562,238	1,368,28
		Other Client/Patient Services	6 & 7	1,052,529	950,67
				7,005,340	6,446,25
	Non Pay				
		Clinical	8	2,306,767	2,066,70
		Patient Transport and Ambulance Services	8	113,065	135,69
		Primary Care and Medical Card Schemes	8	3,923,558	3,642,40
		Other Client/Patient Services	8	30,706	8,76
		Grants to Outside Agencies	8	5,691,382	5,442,82
		Housekeeping	8	362,974	383,63
		Office and Administration Expenses	8	1,002,080	795,21
		Other Operating Expenses	8	11,986	80
		Long Stay Charges Repaid to Patients	9	19	5
		Hepatitis C Insurance Scheme	10	418	1,05
		Payments to State Claims Agency	11	461,331	372,70
		Nursing Home Support Scheme (Fair Deal) - Private Nursing Home only	12	732,887	767,93
				14,637,173	13,617,77
	Total Expe	enditure		21,642,513	20,064,02
Not Operation	ng (Deficit)	Surplus for the Year		(195,034)	200,71

All gains and losses with the exception of depreciation and amortisation have been dealt with through the Statement of Revenue Income and Expenditure and the Statement of Capital Income and Expenditure.

The primary financial statements of the HSE comprise the Statement of Revenue Income and Expenditure, Statement of Capital Income and Expenditure, Statement of Changes in Reserves, Statement of Financial Position and Statement of Cash Flows.

Ciaran Devane	Paul Reid
Chairperson	CEO
27 May 2022	27 May 2022

Health Service Executive Statement of Capital Income and Expenditure

For the year ended 31 December 2021

		Notes	2021 €'000	2020 €'000
Income			005.000	
	Department of Health Capital Grant	3(a)	985,328	1,023,288
	Surplus on Capital Income and Expenditure brought forward	3(b)	0	15,182
			985,328	1,038,470
	Revenue Funding Applied to Capital Projects		1,785	1,724
	Application of Proceeds of Disposals		2,549	9,179
	Government Departments and Other Sources	13(c)	26,573	1,752
			1,016,235	1,051,125
Expenditure				
	Capital Expenditure on HSE Capital Projects	13(b)	609,757	623,989
	Capital Grants to Outside Agencies (Appendix 1)	13(b)	451,940	359,730
			1,061,697	983,719
Not Conital (D	eficit)/ Surplus for the Year		(45,462)	67,406

All gains and losses with the exception of depreciation and amortisation have been dealt with through the Statement of Revenue Income and Expenditure and the Statement of Capital Income and Expenditure.

The primary financial statements of the HSE comprise the Statement of Revenue Income and Expenditure, Statement of Capital Income and Expenditure, Statement of Changes in Reserves, Statement of Financial Position and Statement of Cash Flows.

27 May 2022 27/05/2022	Paul Reid CEO 27/05/2022
27 May 2022	

Health Service Executive Statement of Changes in Reserves For the year ended 31 December 2021

		101	the year er	idea 31 Decei	HUEL ZUZI
	Notes	Revenue Reserves €'000	Capital Reserves €'000	Capitalisation Account €'000	Total €'000
Balance at 1 January 2020(as previously reported)		(1,069,168)	(123,759)	5,252,331	4,059,404
Prior Year Adjustment - Accruais*	26	71,440			71,440
Revised Balance at 1 January 2020		(997,728)	(123,759)	5,252,331	4,130,844
Transfer of (Deficit)/Surplus in accordance with Section 33(3) of the Health Act 2004, as amended	3(b)	(6,472)	(15,182)		(21,654)
Net Surplus for the year		200,711	67,406		268,117
DOH Debtor offset by First Surplus Proceeds of Disposal Account - reserves movement	3(b) 14	(53,990)	(46) 0		(54,036) 0
Additions to Property, Plant and Equipment in the year	13(a)			446,918	446,918
State Investment in PPP Service Concession Arrangements				3,186	3,186
Less: Net book value of Property, Plant and Equipment disposed in year				(6,544)	(6,544)
Less: Depreciation charge in year	15			(226,530)	(226,530)
Balance at 31 December 2020		(857,479)	(71,581)	5,469,361	4,540,301
Balance at 1 January 2021		(857,479)	(71,581)	5,469,361	4,540,301
Transfer of Deficit/(Surplus) in accordance with Section 33(3) of the Health Act 2004, as amended	3(b)	(200,711)	(67,406)		(268,117)
Net (Deficit) for the year		(195,034)	(45,462)		(240,496)
Proceeds of Disposal Account - reserves movement	14		0		0
Additions to Property, Plant and Equipment in the year	13(a)			499,828	499,828
State Investment in PPP Service Concession Arrangements				3,621	3,621
Less: Net book value of Property, Plant and Equipment disposed in year				(40,762)	(40,762)
Less: Depreciation charge in year	15			(256,761)	(256,761)
Balance at 31 December 2021		(1,253,224)	(184,449)	5,675,287	4,237,614

^{*2020} figures have been restated to reflect the impact of the prior year adjustment for accruals, which is a requirement under FRS102.

The primary financial statements of the HSE comprise the Statement of Revenue Income and Expenditure, Statement of Capital Income and Expenditure, Statement of Changes in Reserves, Statement of Financial Position and Statement of Cash Flows.

 Claran Devane
 Paul Reid

 Chairperson
 CEO

 27 May 2022
 27 May 2022

Health Service Executive Statement of Financial Position As at 31 December 2021 2020 €'000 2021 €'000 Notes **Fixed Assets** 5,820,648 5,618,343 Property, Plant and Equipment 15 **Financial Assets** 363 351 **Total Fixed Assets** 5,821,011 5,618,694 Inventories **Current Assets** 16 299,948 359,880 Trade and Other Receivables 17 468,787 415,613 Cash 21 603,789 812,031 Creditors (amounts falling due within one year)* 18 (2,715,379) (2,445,707) Net Current Liabilities (1,342,855) (858,183) Creditors (amounts falling due after more than one year) 19 (162,528)(168,419) **Deferred Income** 20 (78,014)(51,791)Net Assets 4,237,614 4,540,301 **Capitalisation Account** 5,675,287 5,469,361

Capital Reserves

Revenue Reserves*

Capital and Reserves

The primary financial statements of the HSE comprise the Statement of Revenue Income and Expenditure, Statement of Capital Income and Expenditure, Statement of Changes in Reserves, Statement of Financial Position and Statement of Cash Flows.

26

(184,449)

(1,253,224)

4,237,614

(71,581)

(857,479)

4,540,301

 Claran Devane
 Paul Reid

 Chairperson
 CEO

 27 May 2022
 27 May 2022

^{*2020} figures have been restated to reflect the impact of the prior year adjustment for accruals, which is a requirement under FRS102.

Health Service Executive Statement of Cash Flows For the year ended 31 December 2021

	Notes	2021 €'000	2020 €'000
		€ 000	€ 000
Net Cash Inflow from Operating Activities	21	(51,480)	486,412
Cash Flow from Investing Activities			
Cash payments for Capital purposes		(1,057,731)	(966,883)
Cash payments from Revenue for Capital purposes	13(a)	(34,942)	(84,502)
Receipts from sale of property, plant and equipment (excluding trade-ins)	14	2,549	9,179
Net Cash Outflow from Investing Activities		(1,090,124)	(1,042,206)
Cash Flow from Financing Activities			
Capital Grant received		985,328	1,023,288
Capital receipts from other sources	13(c)	26,573	1,752
State Investment in PPP Service Concession Arrangements		(3,621)	(3,186)
Payment of capital element of finance lease		(1,785)	(1,724)
Interest paid on loans and overdrafts		0	(9)
Interest paid on Service Concession Arrangements		(4,911)	(5,025)
Interest paid on finance leases		(816)	(876)
Capital Surplus Transferred to DOH	3(a)	(67,406)	0
Net Cash Inflow from Financing Activities		933,362	1,014,220
Increase in cash and cash equivalents in the year		(208,242)	458,426
Cash and cash equivalents at the beginning of the year		812,031	353,605
Cash and cash equivalents at the end of the year		603,789	812,031

Ciaran Devane Chairperson 27 May 2022 Paul Reid CEO 27 May 2022

Basis of Accounting and Statement of Compliance prepared separately (Word document) Note 1

Operating Deficit Note 2

2021 2020 Net operating deficit for the year is arrived at after charging: €'000 €'000 Audit fees 707 653 Remuneration CEO* 430 426

*The CEO received total remuneration of €430,339. This is comprised of basic pay €363,915, allowances €49,127 and benefit in kind (BIK) €17 208

The BIK amount relates to the provision of a company car, is not a paid allowance and does not increase the overall gross pay. It is calculated

The Distribution relates to the provision or a company can be not a pair anomalized and does not introduce and coordinately coordinate

	2021	2020
Board members' expenses*	€	€
Clarán Devane	362	2,162
Professor Deirdre Madden	0	1,831
Fergus Finlay	0	0
Fiona Ross (resigned 4 August 2021)	0	0
Brendan Whelan (appointed 12 March 2021)	0	0
Anne Carrigy (appointed 12 March 2021)	0	0
Dr Yvonne Traynor	0	0
Tim Hynes	0	0
Aogán Ó Fearghail	0	0
Dr Sarah McLoughlin	0	0
Brendan Lenihan	0	0
Professor Fergus O'Kelly	0	0
	362	3,993

The Board of the HSE was established on 28th June 2019 as governing body of the HSE in accordance with the Health Service Executive (Governance) Act 2019. The Act provides for a Chief Executive Officer who is accountable to the Board but is not a Board member. Fees are paid to Board members.

2021 2020 3(a) Department of Health Revenue and Capital Grant €'000 €'000 21,627,500 Net Revenue Funding allocated to HSE 20,474,829 Less: Capital Funding (985,328) (1,023,288) Less: Once Off funding deferred until 2022* (24,377) Department of Health Revenue Grant 20,617,795 19,451,541

*Once off funding allocations were sanctioned by the relevant Minister towards the end of 2021. These funding allocations have been treated as deferred income to cover expenditure in respect of specific services in Mental Health €7.9m, Disability €6.4m and Palliative Care €10m.

The table below provides further earlier of Department of the life for the control of		
The table below provides further analysis of Department of Health funding received.	2021	2020
	€,000	€,000
Revenue Grant - Funding allocation from the Department of Health	20,617,795	19,451,541
Less: Remittances from Department of Health between 1 January and 31 December	(20,324,347)	(19,451,541)
Revenue Grant balance due from Department of Health 2021 (up to Approved Allocation)	293,448	0
Revenue Grant balance due from Department of Health 2020 (up to Approved Allocation)	0	53.990
Revenue Grant balance due from Department of Health offset against First Surplus 2019	0	(53,990)
Less: Retraction of Revenue First Surplus 2020 to the Department of Health	(200,711)	0
Revenue Grant balance due from Department of Health (up to Approved Allocation) as at 31 December	92,737	0
Capital Grant - Funding allocation from the Department of Health	985,328	1,023,288
Less: Remittances from Department of Health between 1 January and 31 December	(985,328)	(1,023,288)
Capital Grant balance due from Department of Health (up to Approved Allocation) carried forward	0	46
Capital Grant balance due from Department of Health offset against First Surplus 2019	0	(46)
Less: Retraction of Capital First Surplus 2020 to the Department of Health	(67.406)	0
Capital Grant owed to the Department of Health as at 31 December	(67,406)	0
Total Revenue and Capital Grant due from Department of Health, up to Approved Allocation, as at 31 December		
Note 17	25,331	0

3(b) Transfer of (Deficit)/Surplus In accordance with Section 33(3) of the Health Act 2004, as amended

In 2020, the non-Capital Income and Expenditure Account recorded a surplus for the year of £200.7 million and the Capital Income and Expenditure Account recorded a surplus for the year of £200.7 million and the Capital Income and Expenditure Account recorded a surplus of £67.4 million. These surpluses were included in the HSE Reserves at 31 December 2020. In February 2022 the Minister directed, pursuant to Section 33 of the Health Act (as amended), that these amounts should not be carried forward by the HSE against its 2021 Income and Expenditure. In 2021, total payments issued from the Health Vote to the HSE were £239 million test than the amount set out in the Minister's annual letter of determination. The HSE has offset the 2020 surpluses of £200.7 million and £67.4 million. against this debtor giving a net balance owed to the HSE of €25 million

Note 3 Department of Health Revenue and Capital Grant

Note 4 Patient Income

Note 5 Other Income

Health Service Executive Notes to the Financial Statements

	2021	20
	€'000	€'0
Private Charges	219,303	206,9
Inpatient Charges	22,508	20,5
Emergency Department Charges	14,879	11,6
Road Traffic Accident Charges	4,312	3,3
Long Stay Charges	75,821	78,7
EU Income - E111 Claims	5,957	7,2
	342,780	328,5
	2021	20
(a) Other Income	€,000	€'0
Superannuation Income	156,180	159,8
Additional Superannuation Contributions (ASC) deductions from HSE own staff	137,388	130,2
Additional Superannuation Contributions (ASC) deductions from service providers	62,901	61,6
Other Payrol! Deductions	9,015	8,8
Secondment Recoupments of Pay	18,719	18,6
Agency/Services - provided to Local Authorities and other organisations	5,171	8,5
Canteen Receipts	8,841	8,7
Certificates and Registration Income	9,623	8.0
Parking		
Refunds	5,147 14,661	5,2 12,5
Rental Income	3,788	2,4
Donations	1,600	2,3
Legal Costs Recovered	495	2
Income from other Agencies (See Note 5(b) analysis below)	44,265	36,9
Miscellaneous Income	9,110	13,7
	486,904	478,1
	2021	20
	€'000	€'0
(b) Income from Other Agencies *	040	
Department of Foreign Affairs & Trade - Irish Aid: programme for overseas development Friends of St. Luke's Rathgar	243 325	1
Department of Arts, Heritage, Regional and Gaeltacht Affairs - Helicopter Services	207	
Pobal/Slainte Care	7,573	3,7
		3,1
Clinical Trials Ireland - Clinical Research Trials		
Clinical Trials Ireland - Clinical Research Trials EU Income - various projects	676	
Clinicai Triais Ireland - Clinicai Research Triais EU Income - various projects Genio Trust (Mental Health Projects)	676 3,657	6,8
EU Income - various projects	676	6,8 3,8
EU Income - various projects Genio Trust (Mental Health Projects)	676 3,657 4,282	6,8 3,8 1,0
EU Income - various projects Genio Trust (Mental Health Projects) Education and Training Boards/ Solas	676 3,657 4,282 875	6,8 3,8 1,0
EU Income - various projects Gento Trust (Mental Health Projects) Education and Training Boards/ Solas Regional Drug Task Force The Atlantic Philanthropies - National Dementia Strategy Katherine Howard Foundation - Nurture	676 3,657 4,282 875 5	6,6 3,8 1,0 7
EU Income - various projects Genio Trust (Mental Health Projects) Education and Training Boards/ Solas Regional Drug Task Force The Atlantic Philanthropies - National Dementia Strategy Katherine Howard Foundation - Nurture National Treatment Purchase Fund	676 3,657 4,282 875 5 382	6,5 3,8 1,0 7 9 1,1
EU Income - various projects Gento Trust (Mental Health Projects) Education and Training Boards/ Solas Regional Drug Task Force The Atlantic Philanthropies - National Dementia Strategy Katherine Howard Foundation - Nurture National Treatment Purchase Fund UHL Chidren's Ark Development Fund	676 3,657 4,282 875 5 382 242	6,5 3,8 1,0 7 9 1,1 15,3
EU Income - various projects Gento Trust (Mental Health Projects) Education and Training Boards/ Solas Regional Drug Task Force The Atlantic Philanthropies - National Dementia Strategy Katherine Howard Foundation - Nurture National Treatment Purchase Fund UHL Chidren's Ark Development Fund UCC Oncology Clinical Trials	676 3,657 4,282 875 5 382 242 22,751 0 263	6,5 3,8 1,0 7 9 1,1 15,3
EU Income - various projects Genio Trust (Mental Health Projects) Education and Training Boards/ Solas Regional Drug Task Force The Atlantic Philanthropies - National Dementia Strategy Katherine Howard Foundation - Nurture National Treatment Purchase Fund UHL Chidren's Ark Development Fund UCC Oncology Clinical Trials UHW Clinical: Trials	676 3,657 4,282 875 5 382 242 22,751 0 263 296	6,5 3,8 1,0 7 9 1,1 15,3
EU Income - various projects Genio Trust (Mental Health Projects) Education and Training Boards/ Solas Regional Drug Task Force The Atlantic Philanthropies - National Dementia Strategy Katherine Howard Foundation - Nurture National Treatment Purchase Fund UHL Chidren's Ark Development Fund UCC Oncology Clinical Trials UHW Clinical Trials UHW Clinical Trials Nursing and Midwifery Board of Ireland	676 3,657 4,282 875 5 382 242 22,751 0 263 296 333	6,5 3,8 1,0 7 9 1,1 15,3
EU Income - various projects Gento Trust (Mental Health Projects) Education and Training Boards/ Solas Regional Drug Task Force The Atlantic Philanthropies - National Dementia Strategy Katherine Howard Foundation - Nurture National Treatment Purchase Fund UHL Chidren's Ark Development Fund UCC Oncology Clinical Trials UHW Clinica! Trials UHW Glinica! Trials UNISSING and Mildwiffery Board of Ireland Merck Sharp Dohme Clinical Trials	676 3,657 4,282 875 5 382 242 22,751 0 263 296 333 593	6,5 3,8 1,0 7 9 1,1 15,3
EU Income - various projects Gento Trust (Mental Health Projects) Education and Training Boards/ Solas Regional Drug Task Force The Atlantic Philanthropies - National Dementia Strategy Katherine Howard Foundation - Nurture National Treatment Purchase Fund UHL Chidren's Ark Development Fund UCC Oncology Clinical Trials UHW Clinical Trials UHW Clinical Trials Nursing and Midwifery Board of Ireland Merck Sharp Dohme Clinical Trials Bayer Clinical Trials	676 3,657 4,282 875 5 382 242 22,751 0 263 296 333 593 125	6,6 3,6 1,0 7 5 1,1 15,3 1
EU Income - various projects Gento Trust (Mental Health Projects) Education and Training Boards/ Solas Regional Drug Task Force The Atlantic Philanthropies - National Dementia Strategy Katherine Howard Foundation - Nurture National Treatment Purchase Fund UHL Chidren's Ark Development Fund UCC Oncology Clinical Trials UHW Clinica! Trials UHW Clinica! Trials Nursing and Midwiffery Board of Ireland Merck Sharp Dohme Clinical Trials BMS Clinical Trials	676 3,657 4,282 875 5 382 242 22,751 0 263 296 333 593 125	6,6 3,6 1,0 7 9 1,1 15,3 1
EU Income - various projects Gento Trust (Mental Health Projects) Education and Training Boards/ Solas Regional Drug Task Force The Atlantic Philanthropies - National Dementia Strategy Katherine Howard Foundation - Nurture National Treatment Purchase Fund UHL Chidren's Ark Development Fund UHC Concology Clinical Trials UHW Clinical Trials UHW Clinical Trials Nursing and Midwifery Board of Ireland Merck Sharp Dohme Clinical Trials Bayer Clinical Trials BMS Clinical Trials BMS Clinical Trials	676 3,657 4,282 875 5 382 242 22,751 0 263 296 333 593 125 99	6,6 3,8 1,6 5 1,7 15,3
EU Income - various projects Gento Trust (Mental Health Projects) Education and Training Boards/ Solas Reglonal Drug Task Force The Atlantic Philanthropies - National Dementia Strategy Katherine Howard Foundation - Nurture National Treatment Purchase Fund UHL Chidren's Ark Development Fund UCC Oncology Clinical Trials UHW Clinical Trials UHW Clinical Trials Surrsing and Midwifery Board of Ireland Merck Sharp Dohme Clinical Trials Bayer Clinical Trials BMS Clinical Trials BMS Clinical Trials DMG Media- The Pulse Campaign NEIC Development Grant	676 3,657 4,282 875 5 382 242 22,751 0 263 296 333 593 125 99 111 789	6,6 3,8 1,6 5 1,7 15,3
EU Income - various projects Gento Trust (Mental Health Projects) Education and Training Boards/ Solas Regional Drug Task Force The Atlantic Philanthropies - National Dementia Strategy Katherine Howard Foundation - Nurture National Treatment Purchase Fund UHL Chidren's Ark Development Fund UCC Oncology Clinical Trials UHW Clinical Trials UHW Clinical Trials Nursing and Midwifery Board of Ireland Merck Sharp Dohme Clinical Trials Bayer Clinical Trials BMS Clinical Trials DMG Media- The Pulse Campaign NEIC Development Grant Tusla	676 3,657 4,282 875 5 382 242 22,751 0 263 296 333 593 125 99 111 788 262	6,6 3,8 1,6 7 5 1,7 15,8 1,1
EU Income - various projects Gento Trust (Mental Health Projects) Education and Training Boards/ Solas Regional Drug Task Force The Atlantic Philanthropies - National Dementia Strategy Katherine Howard Foundation - Nurture National Treatment Purchase Fund UHL Chidren's Ark Development Fund UCC Oncology Clinical Trials UHW Clinical Trials UHW Clinical Trials Nursing and Midwiffery Board of Ireland Merck Sharp Dohme Clinical Trials BMS Clinical Trials BMS Clinical Trials DMG Media- The Pulse Campaign NEIC Development Grant Tusla Niell Horan Donation	676 3,657 4,282 875 5 362 242 22,751 0 263 296 333 593 125 99 111 789 262 0	6,6 3,8 1,6 7 5 1,7 15,5 11,0
EU Income - various projects Gento Trust (Mental Health Projects) Education and Training Boards/ Solas Regional Drug Task Force The Atlantic Philanthropies - National Dementia Strategy Katherine Howard Foundation - Nurture National Treatment Purchase Fund UHL Chidren's Ark Development Fund UCC Oncology Clinical Trials UHW Clinical Trials UHW Clinical Trials Nursing and Midwifery Board of Ireland Merck Sharp Dohme Clinical Trials Bayer Clinical Trials BMS Clinical Trials DMG Media- The Pulse Campaign NEIC Development Grant Tusla	676 3,657 4,282 875 5 382 242 22,751 0 263 296 333 593 125 99 111 788 262	6,5,6 3,6 1,0 7 9,1 1,1 15,3 1 1,0

^{*}Only income from agencies in excess of €100,000 in either year are shown. Income from Other Agencies that did not exceed €100,000 in either year is shown at Note 5(a) under Miscellaneous Income. Accordingly, the 2020 comparatives above have been re-stated where appropriate.

Health Service Executive Notes to the Financial Statements 2021 €'000 2020 €'000 Pay and Pensions Expenditure Note 6 Clinical HSE Staff Medical/Dental 1,048,912 1,048,654 Nursing 1,837,233 1,724,700 Health and Social Care Professional 726,370 664,303 Superannuation 498,455 472,403 4,110,971 3,910,060 Clinical Agency Staff Medical/Dentai 97,228 95,488 Nursing 122,234 87,277 Health and Social Care Professional 60,140 34,467 279,602 217,232 Non Clinical HSE Staff Management/Administration General Support Staff 819,121 735,908 361,185 351,511 Superannuation 194,875 184,022 1,375,181 1,271,441 Non Clinical Agency Staff Management/Administration General Support Staff 108,851 44,327 78,206 52.518 187,057 96,845 Other Client/Patient Other Patient and Client Care 832,691 764,374 Services HSE Staff Superannuation 118,047 110,278 950,738 874,652 Other Client/Patient Other Patient and Client Care 76,021 101,791 Services Agency Staff 101,791 76,021 Total Pay Expenditure

7,005,340

6,446,251

132,323

126,174

Summary Analysis of Pay Costs

			Other Client/ Patient		
	Clinical	Non Clinical	Services	Total	Total
	2021	2021	2021	2021	2020
	€'000	€'000	€,000	€'000	€'000
Basic Pay	2,723,057	1,000,200	606,857	4,330,114	4,074,480
Allowances	104,002	8,569	23,528	136,099	132,125
Overtime	183,352	19,965	37,022	240,339	210,830
Night duty	68,253	5,608	19,716	93,577	84,311
Weekends	132,564	28,783	65,671	227,018	194,154
On-Call	67,547	1,998	406	69,951	78,011
Arrears	4,998	14,795	1,260	21,052	44,240
Wages and Salaries	3,283,773	1,079,918	754,459	5,118,150	4,818,150
Employer PRSI	328,743	100,388	78,232	507,363	471,299
Superannuation*	498,455	194,875	118,047	811,377	766,704
Total HSE Pay	4,110,971	1,375,181	950,738	6,436,890	6,056,153
Agency Pay	279,602	187,057	101,791	568,450	390,098
Total Pay	4,390,573	1,562,238	1,052,529	7,005,340	6,446,251

Total Pay Costs above relate to HSE services only. Pay costs for employees in the voluntary sector are accounted for under Non-Pay Expenditure (Revenue Grants to Outside Agencies). See Note 8 and Appendix 1.

Superannuation

Eligible staff employed in the HSE are members of a variety of defined benefit superannuation schemes.

Superannuation entitlements (i.e. pensions) of retired staff are paid out of current income and are charged to income and expenditure in the year in which they become payable. In accordance with a Directive from the Minister for Health, no provision is made in the financial statements in respect of future pension benefits and no charge is made to the Statement of Revenue income and Expenditure in respect of this. Superannuation contributions from employees who are members of these schemes are credited to the Statement of Revenue Income and Expenditure when received. No formal actuarial valuations of the HSE's pension liabilities are carried out. The Pension charge to the Statement of Revenue Income and Expenditure for 2021 was €811m (2020: €767m), which included payments in respect of once-off lump sums and gratuity payments on retirement of €143m (2020: €117m).

	*Analysis of Superannuation	2021 €'000	2020 €'000
	Ongoing superannuation payments to pensioners	668,421	650,020
	Once-off lump sums and gratuity payments	142,956	116,684
		811,377	766,704
Termination Benefits		2021 €'000	2020 €'000
	Termination benefits charged to Statement of Revenue Income and Expenditure	294	110
		294	110

The termination benefits above relate to a settlement with one staff member during 2021 (2020: three staff).

In addition to the payments outlined above, no staff member was granted added years on termination. The value of enhanced pension arrangements was

Legal costs of €2,005 (2020: €33,494) were also incurred in relation to concluding the termination agreements.

Note 7 Employment

The number of employees at 31 December by Area of Operation was as follows (in whole time		
equivalents (WTEs)): **	2021	2020*
Acute Services	38,605	36,215
Mental Health	9,918	9,855
Primary Care	11,856	10,872
Disabilities *****	4,192	4,085
Older Persons****	12,872	12,673
Community Health & Welibeing	181	144
Health and Wellbeing	641	511
Ambulance Services	2,060	1,990
Corporate and HBS	5,183	4,847
Total HSE employees	85,508	81,192
Voluntary Sector - Acute Services	29,464	28,234
Voluntary Sector - Non Acute Services	17.351	16,748
Sub-total Section 38 Sector employees ***	46,815	44,982

Total Health Sector Employees **** Source: Health Service Personnel Census

^{*2020} figures are restated to reflect current methodology and organisational mappings

^{**}All figures are calculated to 2 decimals and expressed as whole-time equivalents (WTE) under a methodology as set out by the Department of Health

^{***} Health Sector staffing figures relate to direct employment levels as returned through the Health Service Personnel Census (HSPC) for the public health sector (HSE & Section 38 Voluntary Hospitals & Agencies).

**** Directly employed home help staff are included in reported WTE w.e.f. 2020 and historical figures have been restated to reflect this methodology change. Pre-registration Student Nurses on clinical placement are recorded at 50 percent actual WTE in line with WRC agreement.

^{*****} Disabilities and Older person are two separate divisions now and the comparative figure for 2020 has been revised

Additional Analysis - Department of Expenditure and Reform Circular 13/2014 requirement

The number of HSE employees whose total employee benefits (including basic pay, allowances, overtime, night duty, weekends, on-call, arrears and excluding employer PRSI, employer pension costs) for the reporting period fell within each band of €10,000 from €60,000 upwards are as follows:

Pay Band (Number of Staff)	2024	2020
€60,001 to €70,000	2021	
€70,001 to €80,000	10,822 5,248	10,409 5,211
€80,001 to €90,000		
€90,001 to €100,000	3,093 1,548	2,734
€100,001 to €110,000	785	1,450 676
€110,001 to €120,000		
€120,001 to €130,000	513	439
€130,001 to €140,000	360	285
€140,001 to €150,000	173	158
€150,001 to €160,000	159	137
	145	145
€160,001 to €170,000	178	164
€170,001 to €180,000	190	165
€180,001 to €190,000	164	163
€190,001 to €200,000	169	108
€200,001 to €210,000	166	122
€210,001 to €220,000	187	79
€220,001 to €230,000	164	67
€230,001 to €240,000	197	93
€240,001 to €250,000	108	92
€250,001 to €260,000	86	107
€260,001 to €270,000	56	123
€270,001 to €280,000	50	103
€280,001 to €290,000	46	85
€290,001 to €300,000	23	69
€300,001 to €310,000	10	56
€310,001 to €320,000	9	39
€320,001 to €330,000	9	19
€330,001 to €340,000	10	20
€340,001 to €350,000	6	23
€350,001 to €360,000	1	17
€360,001 to €370,000	4	15
€370,001 to €380,000	2	7
€380,001 to €390,000	2	5
€390,001 to €400,000	2	4
€400,001 to €410,000	1	3
€410,001 to €420,000	2	5
€420,001 to €430,000	3	4
€440,001 to €450,000	0	2
€450,001 to €460,000	Ð	2
€470,001 to €480,000	2	0
€480,001 to €490,000	0	3
€490,001 to €500,000	0	1
€510,001 to €520,000	0	1
€530,001 to €540,000	2	0
€520,001 to €530,001 €590,001 to €600,000	1	0
€640,001 to €650,000	0	1
€680,001 to €690,000	1	0
€750,001 to €760,000	1	0
Total HSE employees in excess of €60,001	24.699	23,412

			Notes to the I	inanciai Stat	ements
				2021	2020
Note 8	Non Pay Expenditure*	* Clinical	Drugs and Medicines (excl. demand led schemes)	€'000	€'000
NOIC O		Chilica:	Less Rebate from Pharmaceutica! Manufacturers*	516,086	341,910
			Net Cost Drugs and Medicines (excl. demand led schemes)	(11,351) 504,735	(9,141)
			Blood/Blood Products	32,190	29,810
			Medical Gases	13,086	11,788
			Medical/Surgical Supplies	630,903	894,520
			Other Medical Equipment	185,457	273,083
			X-Ray/Imaging	69,830	38,703
			Laboratory	622,993	298,486
			Professional Services (e.g. therapy costs, radiology etc.)	173,109	116,449
			Education and Training	74,464	71,093
				2,306,767	2,066,701
		Transport and Ambulanas Candons			
		Transport and Ambulance Services	Table 1 Table port	61,807	59,067
			Vehicles Running Costs	21,169	17,345
			Transport and Logistical relating to purchase of PPE	30,089	59,278
				113,065	135,690
		Primary Care and Medical Card	Pharmaceutical Services	2,700,027	2,537,829
		Schemes	Less Rebate from Pharmaceutical Manufacturers*	(230,675)	(186,896)
			Less Prescription Levy Charges	(61,682)	(79,704)
			Net Cost Pharmaceutical Services	2,407,670	2,271,229
			Doctors' Fees and Ailowances	872,514	808,457
			Pension Payments to Former District Medical Officers/Dependents	1,637	2,059
			Dental Treatment Services Scheme	39,190	40,074
			Community Ophthalmic Services Scheme	24,869	22,313
			Cash Allowances (Blind Welfare, Mobility etc.)	31,059	30,881
			Capitation Payments:		
			Treatment Abroad Schemes and Related Expenditure	53,850	49,460
			Intellectual/Physical Disabilities, Psychiatry, Therapeutic Services etc.	340,597	296,386
			Elderly and Non-Fair Deal Nursing Home Payments	106,816	78,853
			Rehabilitative and Vocational Training	25,785	26,255
			Respite Beds	19,571 3,923,558	16,438 3,642,405
				0 020,000	0,042,400
		Other Client/Patlent Services	Professional Services	29,836	8,015
			Education and Training	870	746
				30,706	8,761
		Grants to Outside Agencies	Revenue Grants to Outside Agencles (Appendix 1)	5,691,382	5,442,823
				5,691,382	5,442,823
		Housekeeping	Catering	67,427	65,926
			Heat, Power and Light	72,125	65,791
			Cleaning and Washing	179,628	187,104
			Furniture, Crockery and Hardware	23,842	23,011
			Bedding and Clothing	19,952	41,798
				362,974	383,630
		Office and Administration Expenses	Maintenance	222,591	157 204
			Finance Costs	3,302	157,291 3,242
			Prompt Payment Interest and Compensation	921	467
			Insurance	7,659	6,770
			Audit	707	653
			Legal and Professional Fees	197,980	102,300
			Bad and Doubtful Debts	21,558	70,114
			Education and Training	15,063	12,509
			Travel and Subsistence	62,328	61,537
			Vehicle Costs	5,183	6,932
			Office Expenses	203,652	161,011
			Rent and Rates	131,391	108,210
			Computers and Systems Maintenance	129,745	104,174
				1,002,080	795,210
		Other Operating Expenses	Licences	1,065	1,037
			Sundry Expenses	7,603	(3,889)
			Burial Expenses	117	174
			Recreation (Residential Units)	1,025	729
			Materials for Workshops	170	216
			Meals on Wheels Subsidisation	1,529	1,508
			Ex Gratia Payments to Patients (Cervical Check) Refunds	477	288
			:Sorunua	477 11,986	744 807
			and special arrangements for specific druce and medicines	11,300	007

^{*}In respect of 2016 IPHA Agreement and special arrangements for specific drugs and medicines.

^{**}Note 1(b) provides additional analysis in respect of material year on year increases

The Health (Repayment Schome) Act 2006 provides the legislative basis for the repayment of what has been referred to as long stay charges, which were incorrectly levied on persons with full medical card eligibility prior to 14 July 2005. The scheme allows for the repayment of charges to the following people:

- Living people who were wrongly charged at any time since 1976
- The estates of people who were wrongly charged and died on or after 8 December 1998

A special account was set up which is funded by monies provided by the Circachtas and from which repayments are made. An amount of €1.7m was set aside in 2021 for this purpose. The majority of this funding refers to a provision for payments that will arise as a result of follow-on claims and offer acceptances.

The scheme closed to new applicants on 31 December 2007 and nearly 14,000 claims have been received in respect of living patients and nearly 27,000 claims in respect of estates. Up to 31 December 2021, 20,303 claims were paid. As at December 2021, there were no outstanding claims being processed to offer stage under the scheme. €0,600m has been provided in the HSE's 2022 budget to fund repayments for outstanding claims and associated administrative costs.

The cumulative total expenditure of the scheme (including administrative costs) to 31 December 2021 is €485.94m.

In 2021, the following expenditure has been charged to the Statement of Revenue Income and Expenditure in respect of the Repayments Scheme:

	2021	2020
	€.000	€'000
Pay	0	23
Non Pay		
Repayments to Patients	19	55
Payments to Third Party Scheme Administrator	0	0
	19	55
Legal and Professional Fees	0	0
Office Expenses*	3	21
Total Non Pay	22	76
Total	22	99

*All expenditure in relation to the Health (Repayment Scheme) Act 2006 is included in HSE expenditure

The Hepatitis C Compensation Tribunal (Amendment) Act 2006

The Hepstitis C Compensation Tribunal (Amendment) Act 2006 established a statutory scheme to address insurance difficulties experienced by persons infected with Hepstitis C and HIV through the administration within the State of blood and blood products. This scheme addresses the problems faced by these persons due to their inability to purchase mortgage protection and life assurance products are result of contaminated blood products being administered to them. The scheme covers the Insurance is for the 1,700 or more people entitled to avail of assurance products, regardless of any other medical conditions these people may have, once they pay the standard premium that an uninfected person of the same age and gender would pay. The life assurance element of the scheme was isunched by the HSE in September 2007. A further element, providing for travel insurance cover, was introduced in March 2009.

The overall cost over the lifetime of the scheme was originally estimated at €90m. The cumulative expenditure on the insurance scheme to 31 December 2021 was €12.7m.

In 2021, the following expenditure has been charged to the Statement of Revenue income and Expenditure in respect of the insurance Scheme;

	2021	2020
	€,000	€'000
Pay	93	91
Non Pay		
Payments of premium loadings	218	233
Payments of benefits underwritten by HSE	200	821
	418	1054
Office Expenses*	4	14
Total Non Pay	422	1,068
Total**	515	1,159

*All expenditure in relation to the Hepatitis C Compensation Tribunal (Amendment) Act 2006 is included in HSE expenditure.
***These costs are included in the Hepatitis C Insurence Scheme Special Account. Other Hepatitis C Costs are included in the Hepatitis C Special Account and the Hepatitis C Reparation Account.

Note 11

State Claims Agency Since 1 July 2009, the HSE is funded for claims processed by the State Claims Agency under the terms of the Clinical indemnity Scheme. From 1 January 2010, the National Treasury Management Agency (Delegation of Functions) Order 2009 extended the State indemnity to personal injury and third party property damage claims against the HSE. Awards paid to claims to under the terms of the scheme are accounted for one apy-as-you-po basis. The State Claims Agency's best current estimate of the ultimate cost of resolving each claim, includes all foresceable costs such as settlement amounts, plaintiff legal costs and defence costs such as fees payable to counsel, consultants etc. In 2021, the charge to the Statement of Revenue income and Expenditure was 6461.3m (2020: 6372.7m). Based on actuarial estimates, the charge to the Statement of Revenue income and Expenditure was 6461.3m (2020: 6372.7m). Based on actuarial estimates, the charge to the Statement of Revenue income and Expenditure was 6461.3m (2020: 6372.7m). Based on actuarial estimates, the charge to the Statement of Revenue income and Expenditure is expected to increase significantly in future years. In accordance with the directions of the Minister for Health, no provision has been made for this liability in the financial statements.

The estimated liability is ravised on a regular basis in light of any new information received for example past trends in settlement amounts and legal costs. At 31 December 2021, the estimated liability incurred to that date under the Clinical Indemnity Scheme and State Indemnity was €4,185m (2020 €3,887m). Of this €4,185m, approximately €3,408m relates to active claims in respect of clinical care, with the balance of the estimated liability relating to non-clinical care claims. Active claims are those that have been notified to the State Claims Agency through legal process and that have not yet concluded as at the reporting date.

Note 12

Long Term

The Nursing Homes Support Scheme (Fair Deal) commenced in 2008 and phases out the former Nursing Homes Subvention Scheme and the 'contract bada' system for older persons.

Residential Care
(Incorporating Nursing
Homes Support Scheme (Fair Deal) commenced in 2008 and phases out the former Nursing Homes Subvention Scheme and the 'contract bada' system for older persons.

Under the scheme, people who need long term residential care services have their income and assets assessed, and then contribute up to 80% of assessable income and up to 7.5% per (Incorporating Nursing Homes Subvention Scheme and the 'contract bada' system for older persons.

The Nursing Homes Subvention Scheme and the 'contract bada' system for older persons.

The Nursing Homes Subvention Scheme and the 'contract bada' system for older persons.

The Nursing Homes Subvention Scheme and the 'contract bada' system for older persons.

The Nursing Homes Subvention Scheme and the 'contract bada' system for older persons.

The Nursing Homes Subvention Scheme and the 'contract bada' system for older persons.

The Nursing Homes Subvention Scheme and the 'contract bada' system for older persons.

The Nursing Homes Subvention Scheme and the 'contract bada' system for older persons.

The Nursing Homes Subvention Scheme and the 'contract bada' system for older persons.

The Nursing Homes Subvention Scheme and the 'contract bada' system for older persons.

The Nursing Homes Subvention Scheme and the 'contract bada' system for older persons.

The Nursing Homes Subvention Scheme and the 'contract bada' system for older persons.

The Nursing Homes Subvention Scheme and the 'contract bada' system for older persons.

The Nursing Homes Subvention Scheme and the 'contract bada' system for older persons.

The Nursing Homes Subvention Scheme and the 'contract bada' system for older persons.

The Nursing Homes Subvention Scheme and the 'contract bada' system for older persons.

The Nursing Homes Subvention Scheme and the 'contract bada' system for older pers

Costs of Long Term Residential Care (Nursing Homes Support Scheme/Fair Deal)

	€,000	€'000
Private Nursing Homes	655,704	657,663
Section 39 Agencies	21,475	21,950
Private Nursing Homes Contract Beds and Subvention Payments	7,625	10,805
Covid 19 Temporary Assistance Payment Scheme (TAPS) **	48,083	77,520
Total Payments to Private Nursing Homes including Section 39 Agencies	732,887	767,938
Gross NHSS Cost of Public Nursing Homes*	331,417	356,191
Payments to Section 38 Agencies	24,555	26,410
Nursing Home Fixed and Other Unit Costs	109,947	57,407
Total Long Term Residential Care	1,198,808	1,207,946

*Public nursing homes costs are included under the relevant expenditure headings in the Statement of Revenue income and Expenditure.

**Covid 19 Temporary Assistance Payment Scheme (TAPS)

The support under the scheme is a temporary assistance payment, being offered to support private and voluntary Nursing Homes to continue to build resilience within their service to mitigate against a COVID-19 outbreak and be capable of managing an outbreak in terms of providing safe staffing and environment should an outbreak occur.

The Intention to establish the Scheme was announced on 4th April 2020 and the Scheme first opened for applications on 17th April 2020. In 2021, the cost of the Covid 19 Temporary Assistance Payment Scheme (TAPS) was €48.08m (2020: €77.5m).

Patient contributions

NHSS recipient contributions for those patients in public homes amounted to €59.05m (2020; €62,80m) and are included in the HSE Financial Statements - Revenue Income & Expenditure Account

NHSS recipient contributions for those patients in voluntary centres (\$38 Organisations) amounted to €6.30m (2020: €6.67m), and is retained by those centres and does not constitute income for the HSE.

Additional Incom

Under Section 27 of the Nursing Homes Support Scheme Act 2009, a Schedule of Assets must be submitted to the HSE in respect of a deceased person who received financial support undor the Scheme. This is checked to identify and calculate any overpayment of financial support that it is repayable to the HSE pursuant to Section 42 of the Act. The HSE collected income of 48.92m during 2012 (2002): 67.28m) in respect of non-declared income and assets of Fair Deat clients.

Contract beds and Subvention beds in 2021, e10.81m) were made in relation to contract beds and nursing home subvention. These schemes are being phased out having had no new entrants alrow the Nursing Homes Support Scheme commenced in 2009.

Experiously evaluate because learnings
Within the public homes in 2021 there was an additional €109.95m (2020: €57.41m) of costs relating to long term care. These costs related to fixed unit costs and other costs incurred which were in excess of the reimbursed money follows the patient, rate paid under the Nursing Homes Support Scheme.

in 2921, the cost of public nursing homes amounted to €331.42m (2020 €356.19m), these costs are gross and the client contribution element amounted to €59.05m (2020 €32.8m). The contributions are recognised as income in Long Stay Charges in Statement of Income and Expenditure.

Ancillary State Support

Anothery State Support is an optional extra feature of the Nursing Homes Support Scheme for people who own property or assets in the State, Instead of a person paying their assessed contribution for care from their own resources, a person can choose to apply for a Nursing Home Loan, to cover the portion of their contribution, which is based on property or land-based assets within the State. The HSE then pays that portion of the cost of care on top of the State Support payment. The loan is paid back to the State following the occurrence of a relevant event e.g. sale of the asset or death of the person. Repayment of the loan is made to the Revenue Commissioners. In certain cases, repayment of the loan can be deferred. This part of the scheme is designed to protect people from having to sell their home during their lifetime.

The total gross amount of Ancillary State Support advised to Revenue as at 31 December 2021 for recoupment from the commencement of fine Nursing Homes Support Scheme (where a relevant and non-relevant event has occurred) was @260,98m, representing 10,692 citient loans. As at 31st December 2021 the Revenue Commissioners are collecting @269,99m, representing 10,793 citients. The difference accounts for citients where their Nursing Home loan is not due for repayment such as the Further Deferral option, as mentioned above, and also citients who wish to make a violentary repayment prior to a relevant event occurring. The Revenue Commissioners have confirmed that they had received €182.46m of loans repayments paid in full, representing 8,116 citient loans.

The total amount of Nursing Home Loan payments made under the Nursing Homes Support Scheme that are outstanding (i.e. where a repayable amount has not been notified to Revenue for collection - a relevant event has not occurred), as at 31 December 2021 is €161.82m. This amount does not include an adjustment for CPI as a relevant event has not yet occurred.

2021	2021	2020	2020
€,000	Number of	€'000	Number of loans
	loans		
260,975	10,692	211,374	9,179
(182,458)	(8,118)	(142,603)	(6,769)
78,517	2,576	68,771	2,410
161,819	5,099	151,321	5,035
240,338	7,675	220,092	7,445
	280,975 (182,458) 78,517 161,819	6'000 Number of loans 260,975 10,692 (182,458) (8,118) 78,517 2,576 161,819 5,099	€'000 Number of loams €'000 280,975 10,682 211,374 (*82,458) (8,119) (142,603) 78,517 2,576 68,771 161,819 5,099 151,321

			2021	2020
	Capital			
Note 13	Expenditure	(a) Additions to Fixed Assets	€,000	€.000
	Exhautaina	Additions to Property, Plant and Equipment (Note 15) Land and Buildings - Service Concession*	0	0
		Additions to Property, Plant and Equipment (Note 15) Land and Buildings - Other	279,178	228,343
		Additions to Property, Plant and Equipment (Note 15) Other than Land and Buildings	220,650	218,575
			499,828	448,918
		Funded from Department of Health Capital Grant	464,886	362,416
		Funded from Department of Health Revenue Grant	34,942	84,502
		Capitalised - Investment in PPP Service Concession Arrangements*	0	0
			499,828	448,918
			2021	2020
		(b) Analysis of Expenditure Charged to Statement of Capital Income and Expenditure	€,000	€,000
		Expenditure on HSE's own assets (Capitalised)	464,886	362,415
		Expenditure on HSE projects not resulting to property, plant and equipment additions**	141,250	258,388
		Capitalised Interest - PPP Service Concession Arrangements*	3,621	3,188
		Total expenditure on HSE Projects charged to capital***	609,757	623,989
		Capital grants to outside agencies (Appendix 1)**	451,940	359,730
		Total Capital Expenditure per Statement of Capital Income and Expenditure	1,061,697	983,719

^{*}Relates to Primary Care Centre assets acquired under Public Private Partnership (PPP) service concession arrangements.

Note 14

newes to mining Care Centre essents exquired whose multi-crimate returnship (mm) step (mm) argements.

***Total capital expenditure not capitalised emounts to £598.80m (2020: £561.10m)

***Capital funded assets and Revenue funded assets are capitalised if the cost exceeds certain value thresholds: £2,000 for computer equipment and £7,000 for all other asset classes.

(c) Analysis of Capital Income from Other Sources		2021	2020
income from Government Departments and Other Source	s in respect of Capital Projects:	€,000	€.000
Sustainable Energy Authority of Ireland (SEAI) - Energy s	avings in acute hospitals	3,762	1,605
National Rehabilitation Hospital Foundation-Contribution	towards National Rehabilitation Hospital	10,000	0
Mid Western Development (JP McManus) Contribution to	wards Croom Hospital	3,000	0
Department of Education- Contribution towards National	Children's Hospital	3,500	0
University of Cork - CUH Academic Centre Project Contril	outlon	182	126
Presentation Brothers- Contributions towards National Ch	ildren's Hospital	500	D
Friends of St Theresa Hospital Clogheen		215	0
Other Miscellaneous Income		5,414	21
Total Capital Income from Other Sources		26,573	1,752
		2021	2020
		€'000	€,000
Proceeds of Disposal Gross Proceeds of all Disposals in year		2,572	9,225
of Fixed Asset Less: Net Expenses Incurred on Disposals		(23)	(46)
Account Net Proceeds of Disposal		2,549	9,179
Less Application of Proceeds		(2,549)	(9,179)
Movement in the year		c	0
At 1 January		38	38
Balance at 31 December		38	38

The Multi-Annual Delegated Capital sanction 2019-2022 was issued in December 2019 by the Department of Public Expenditure and Reform.

Property, Plant and Equipment Note 15

Cost / Valuation	Land*	Buildings** €'000	Work in Progress (L&B) €'000	Motor Vehicles €'000	Equipment €'000	Work in Progress (P&E) €'000	Total 2021 €'000
At 1 January 2021	1,675,332	4,827,881	397,510	105,554	1,749,786	11,174	8,767,237
Additions	748	14,565	263,866	13,442	196,143	11,066	499,828
Transfers from Work in Progress	0	365,468	(365,468)	9,688	693	(10,381)	0
Disposals	(122)	(4,125)	(439)	(13,493)	(60,362)	(48)	(78,590)
At 31 December 2021	1,675,958	5,203,789	295,489	115,191	1,886,260	11,810	9 188 475
Depreciation							
Accumulated Depreciation at 1 January 2021	0	1,638,723	0	78,833	1,431,338	0	3,148,894
Charge for the Year	0	123,485	0	14,447	118,826	9	258,761
Disposals	0	(1,785)	.0	(12,310)	(23,733)	0	(37,828)
At 31 December 2021	0	1,760,423	0	80,970	1,528,434	0	3,367,827
Net Book Values							
At 1 January 2021	1,675,332	3,189,158	397,510	26,721	318,448	11,174	5,618,343
At 31 December 2021	1,675,958	3,443,366	295,469	34,221	359.826	11,810	5 820 648
The current cerrying value of land amounting to €1.67bn held by the HSE et 31 December	er 2021 is based	on the 2002 De	partment of Hea	alth Valuation ret	tes.		
Building assets held under Finance Leases/ Service Concession Arrangements		2021	2020	2021	2020	2021	2020
		€,000	€,000	€,000	€,000	€,000	€,000
		Finance	Finance	Service	Service	Total	Total
		Lease	Lease	Concession*	Concession*		
Cost		45,824	45,824	165,217	165,217	211,041	211,041
Additions		0	0	0	C	C	0
Accumulated Depreciation at 1 January		(27,209)	(25,34?)	0	0	(27,209)	(25,347)
Depreciation charged for the year		(1,862)	(1,862)	0	0	(1,862)	(1,862)
Net Book Values at 31 December		16 753	18,615	185,217	165,217	181,970	183,832

*** Relates to Primary Care Centre (PCC) essets ecquired under Public Private Partnership (PPP) service concession arrangements. ## fourteen PCC sites news reached service commencement.

PCC Assets are not deprecisted where they have been acquired or are managed under service concession agreements which guarantee residual useful itses and operating capacity at the end of the concession term that would be equivalent to that of the asset when it was first commissioned.

Note 16 inventories

	299,948	359,880
Sundries	1,370	3,548
Stationery and Office Supplies	2,254	2,114
Household Services	33,672	30,721
Vaccine Inventories	66,597	35,816
Blood and Blood Products	1,604	1,420
Pharmacy Dispensing Inventories	490	508
High Tech Pharmacy Inventories	43,714	44.813
Pharmacy Supplies	27,709	27,716
Laboratory Supplies	2B,483	7,211
Medical, Dental and Surgical Supplies	94,055	206,013
	€'000	€'000
	2021	2020

The movement in inventory in 2021 is mainly stributable to the reduction in the PPE stock levels offset by an increase in the level of Vaccine Stocks and year end stocks of antigen tests.

PPE Stocks of €73.4m (2020: €182.3m) are included in medical, dental & surgical supplies (€47.1m) and also in household services (€26.4m). The cost of PPE stocks purchased in 2021 continued to be significantly infasted due to the on-going COVID-19 environment. The HSE is required to revalue flat year end stocks on the basis of the fower of cest or replacement cost. Consequently, PPE stocks has been revaluad resulting in a cost price impairment of €70.6m in 2021. These is also a provision of €25.6m recorded in 2021 related to surplus stocks of hard-gels which the HSE considers may expire before they can be utilised in our services. The HSE has ser-marked certain items of PPE which it intends to donate as part of on-going state support to countries in lead of assistance, the cost of this is in the order of €12.6m. The overall impairment loss of €108.6m is included as a write down in current revenue expenditure as reported in note 1(b).

Vaccine stocks have increased by €30m mainly due to the need to maintain COVID-19 Vaccinations for the on-going Vaccination Programme. Laboratory supplies have also increased as these include Antigen tests of €21m required as part of the HSE's Test and Trace Programme.

2021

2021

2020

2020

Trade and Other

2021 2020 €000 Receivables: Patient Debtors - Private Facilities in Public Hospitals* 106.093 76.868 Receivables: Patient Debtors - Public Inpatient Charges Receivables: Patient Debtors - Long Stay Charges 8,615 5,916 9,087 9.761 Prepayments and Accrued Income 63,978 25,331 37,987 Department of Health (DoH) Debtor (Note 3a) B1.818 Pharmaceutical Manufacturers 108.215 Payroli Technical Adjustment 14,266 15,087 Additional Superannuation Contributions (ASC) Deductions from Staff 6 887 6.294 Local Authorities Payroll Advances 17 1.712 Voluntary Hospitals - National Medical Device Service Contracts 52.002 89.519 Voluntary Hospitals - Grant Funding Advances Sundry Receivables 73,818 90,117 468.787

*Private Healthcare insurance income

in line with the HSE's accounting policy the HSE recognises patient income due from private health insurance companies at the time the service is provided. During 2017 a number of insurance companies commenced deductions from claims made by the HSE relating to the time period between the date of admission and the date the Private insurance Patient form with a signed by the patient. The HSE has disputed those though a legal process which at the time of preperation of these accounts has not fully concluded. In line with the HSE's accounting policy bad and doubtful debt provision is created in relation to debts outstanding for more than one year.

	2.715,379	2,445,707
Sundry Payables	20,717	24,235
Lottery Grants Payable*	592	2,590
Department of Public Expenditure and Reform - Single Public Service Pension Scheme	10,376	5,383
Taxes and Socie! Welfare	259,031	222,054
Accruals Pay**	581,421	551,177
Accruals - Grants to Voluntary Hospitals and Outside Agencies**	530,534	494,328
Accruals Non Pay - Capital	8,641	7,199
Accruels Non Pay - Revenue**	1,024,760	953,038
Payables - Capital	15,750	21,759
Payables - Revenue	255,761	156,633
Service Concession Liability	4,939	4,518
Finance Leases	2,857	2,795
	€ 000	€ 000

"The HSE administers the disbursement of National Lottery grants for local programmes under the National Lottery's Health and Welfare Funded Schames. The balance represents funding approved but not yet disbursed to grant recipients at year end.

**During 2021, the HSE conducted an in-depth technical review of over 78% of its non-pay accruals, noting that over a number of years (between 2005 & 2019), a subset of accruals and provisions totaling 645.5m were not deemed valid. An additional 625.5m of accruals for pay and grants were also deemed invalid. In compliance with FRS102, this was recorded as a prior year adjustment totaling 671.4m by restating the opening balances in liabilities and equity for the earliest period. See Note 26.*

Creditors (amounts falling due after mon than one year) Note 19

		€,000	€.000
	Finance Leases	22,103	23,951
9	Service Concession Liability	140,425	144,488
	Total Finance Lease obfigations	162,528	168,419

Deferred income Note 20

	2021	2020	
Deferred income comprises the following:	€000	€.000	
Department of Health Revenue funding deferred (Note 3A)			
Mental Health	7,947	0	
Palifiative Care	t0,000	0	
Disabilities	6,430	0	
Total Department of Health Deferred	24,377	0	
Other Deferred Income:			
Donations and bequests*	19,578	19,433	
Grant Funding from the State and other bodies	27,588	27,757	
Funding from specific capital projects	2,811	390	
General	3,860	4.211	
Balance at 31 December	78,014	51.791	

*Unspent income arising from donations and bequests where the purposes to which money may be applied has been specified but the related expenditure has not been incurred.

2021

2020

					€'000	€,000
Note 21	Net Cash inflow from Operating Activities	Surplus/(Deficit) for the current year			(195,034)	200,711
	a portating 7 total 1.00	Prior Year Adjustment re Accruais transferred to Reserves* Capital element of lease payments charged to revenue			1.784	71,440
		Purchase of equipment charged to Statement of Revenue Income and Expenditure			34,942	84,502
		Finance Costs charged to Statement of Revenue income and Expenditure			815	885
		(Increase)/Decrease in Inventories			59,932	(189,718)
		(Increase)/Decrease in Trade and Other Receivables			(53, 173)	(18,442)
		Increase/(Decrease) in Creditors (failing due within one year)*			273,754	339,789
		Revenue Reserves - transfer of Deficit in accordance with Section 33(3) of the Health Act, 2004, as amended			(200,711)	(6,472)
		Share Revaluation			(12)	9
		increase/(Decrease) in Deferred income		-	26,223	1,984
		Net Cash Inflow from Operating Activities		÷ =	(51,480)	486,412
		*2020 figures have been restated to reflect the impact of the prior year adjustment for accruals, which is a requirement of	inder FRS102, Sec	note 26.		
Note 22	Commitments				2021	2020
	Capital Commitments	Future Property, Plant and Equipment purchase commitments:			£000	€,000
		Within one year			1,057,427	990,617
		After one but within five years			1,993,485	2,365,720
				0	3,050,912	3,356,337
		Contracted for, but not provided for, in the financial statements			1,223,952	1,613,926
		Included in the Capital Plan but not contracted for		-	1,826,960	1,742,411
					3,050,912	3,356,337
		The HSE has a multi-annual Capital Investment Plan which prioritises expenditure on capital projects in tine with goals is commitments identified above are in respect of the total cost of projects for which specific funding budgets have been as years after 2021 for which budgets have yet to be approved and are therefore estimated.				
					2021	2020
	Operating Lease	Operating lease rentals (charged to the Statement of Revenue income and Expenditure)			€,000	€,00D
	Commitments	Land and Bulldings			86,321	62,181
		Motor Vehicles Equipment			504 1.482	471
		Equipment		-	88,307	1.293 63,945
			Land and		00,000	00,010
			Buildings	Other	Total	Total
		The HSE has the following total amounts payable under non-cancellable operating leases split between amounts due:	2021	2021	2021	2020
			€'000	€'000	€,000	€,000
		Within one year	58,692	1,147	59,839	51,538
		In the second to fifth years inclusive	207,257	704	207,961	185,754
		in over five years	547,278 813,227	1,851	547,278 815,078	493,228 730,518
			013,227	7,001	010,070	730,018
					2021	2020
	Public Private Partnership Forward	Nominal Amount:			€,000	€,000
	Commitments	Service Concession Arrangement - Primary Care Centres (14 sites bundle)			183,339	188,883
		These commitments incorporate facilities management services, operational, and lifecycle costs, for the remaining life of	f the agreement. T	hey are not d!	scounted to prese	nt value.
	Finance Lesse	The future minimum lease payments at 31 December are as follows:	2021	0000	999.	00
	Commitments	The second state of the second	2021 €'000	2020 €'600	2021 €'000	2020 €'000
			Finance	Finance	Service	Service
			Lease	Lease	Concession*	Concession*
		Not later than one year	3,600	3.600	9,716	9,418
		Later than one year but not later than five years	12,640	12,080	36,264	35,882
		Later than five years	12,310	15,470	158,055	167,267
		Total Gross Payments	(3.590)	31,150 (4,405)	204,035 (58,671)	212,567
		Less: Finance Charges Carrying Amount of Liability	24,960	28.745	145.364	(63,583) 148,984
		Classified as;	24.000	20,140	140.304	1401904
		- Creditors (amounts failing due within one year)	2,857	2,794	4,939	4,518
		- Creditors (amounts failing due after more than one year)	22,103	23,951	140,425	144,468
		*The value of the PCC asset and the service concession liability is recognised as assets and liabilities in the Statement of present value of the minimum lease narments. In line with ERS 102, the effective interact rate is used to discount the first	Financial Position	at an amount	of €165.2m which	is equal to the

*The value of the PCC asset and the service concession liability is recognised as assets and liabilities in the Statement of Financial Position at an amount of £165.2m which is equal to the present value of the minimum lease payments. In line with FRS 102, the effective interest rate is used to discount the future construction related liabilities erising from concession agreements. The carrying amount of the liability at 31 December 2021 is £145.36m.

Note 23 Property

The HSE estate comprises 2,610 properties 2021 2020 Title to the properties can be analysed as follows: Number of Properties Number of Properties 1,583 1 574 Leasehold 1.036 989 Total Properties 2,610 2,572 ation of the properties can be analysed as follows: 2.520 Delivery of health and personal social services 2.484 Health Business Services and Support (Including medical card processing etc.) 90 Total Properties 2,610 2,572

Ouring the year there were 68 property additions to the healthcare estate and 31 properties were removed through both disposals and lease terminations. The net result is a increase of 38 healthcare properties during 2021. The total number of properties in the HSE healthcare estate at the end of 2021 has been impacted by a combination of routine estate management activities as well as the requirements of specific key healthcare strategies to deliver ongoing rotlout of princip received in rotlocation of disability services to community settings.

Note 24 Tavation

The HSE carried out a significant self-review of tax compliance in respect of 2020 with external specialist tax assistance which was completed in 2021. The self-review was conducted on an agreed risk based assessment with Revenue under their co-operative compliance framework. As the level of review for 2020 was impacted by Covid19 staffing requirements, and the Cyber Attack, it was agreed with Revenue to perform a review focussed on specific areas which gave rise to the eignificant habilities in previous years. The liability to taxes identified in the course of the self-review for 2020 was set out by means of a Self-Correction disclosure and payment (including interest) of €2,65,172 was made to the Revenue Commissioners in September 2021. The amount represents 0.12% of the overall tax paid by the HSE for that year. The HSE has a dedicated in house tax team resourced by tax professionals developing a strong reliationship with Revenue and with access to external advisors where necessary. The HSE remains committed to exemplary tax compliance.

Contingent Liabilities General Note 25

The HSE is involved in a number of claims involving legal proceedings which may generate itabilities, depending on the outcome of the litigation. The HSE has insurance cover for professional indemently, fire and specific all risk claims, in most cases, such insurance would be sufficient to cover all costs, but this cannot be certain due to indemnity limits and policy conditions. The financial effects of any uninsured contingencies have not been provided in the financial statements.

Clinical Indemnity Scheme Details of the contingent liability in respect of the Clinical Indemnity Scheme are set out in Note 11.

Note 26

Prior Year Adjustment. The financial statements disclose the funding and expenditure incurred on the health services and activities delivered and administered by the HSE. This enables users of the financial statements to understand, among other things, the extent to which the HSE is meeting its service delivery and other operating and financial objectives. Where corrections or adjustments are required to previously reported figures, these are made and disclosed in accordance with accounting rutes (FRS 102) so that the impact on financial performance and position can be assessed and meaningful financial comparison can be undertaken between years.

The HSE uses the system of accruals accounting, the common form of accounting among most organisations. This system includes making estimates and judgements for the cost of goods and services consumed but not paid for at the reporting year—end. The sums of money estimated are included in the current year's accounts, although they are not actually spent until the following year. Each year therefore, a non-cash adjustment is made to the accounts to properly each into for the issue.

in preparing the 2021 financial statements, a non-cesh adjustment of €7.1.4 million was identified relating to accrued expenditure that the HSE had anticipated it would have to pay out in later periods. However having reviewed this area in detail, the HSE is now clear that these payments will not now arise after all. Accordingly, the charge to expenditure has been reversed in the Statement of Changes in Reserves by reducing the accumulated revenue deficit at the start of 2020 by €7.1.4 million to €99.7.7 million. The cumulative €7.4.4m adjustment for the prior years is material: only in the context of restating the carrying value of accorded expenditure or the Balancian adjustment is non-cash impacting, it does not increase expenditure but reduces it, and does not require any additional funding to be provided and therefore does not impact on the delivery of HSE services to patients or service users.

This accrued expenditure of €71.4 million had built up over a number of financial years, with the more significant accruals arising between 2018 and 2019. The highest adjustment identified in any one of these years (€16.3 million) occurred in 2018 when the annual allocation required to deliver public health services was €15.2 billion. The HSE has concluded that there was no material impact on the Income and Expenditure in the financial statements in any of the affected years. The HSE's Statement of Internal Control (SIC) provides more detail on the prior year adjustment.

This adjustment is not the correction of a fundamental error. Up to the implementation of the current accounting standard (FRS102) in 2015, prior year adjustments were rare and were reserved for very limited circumstances, including where there was an error in the financial statements likel testroyed their truth and fairness. Since 2015, prior year adjustments are used more frequently in financial statements, including to improve comparability between reporting periods. For the avoidance of doubt, had the higher level of HSE socreties carried on the HSE Balance Sheet been corrected, none of the necessary adjustments would have threatened the truth or fairness of the financial statements or qualified in previous years as a

Note 27 Related Party

The Health Service Executive adopts procedures in accordance with the Department of Public Expenditure and Reform's Code of Practice for the Governance of State Bodies, the Ethics in Public Office Act 1965 and the Standards in Public Office Act 2001, in relation to the disclosure of interests of the Health Service Executive. Those procedures have been adhered to a the HSE during the year. A number of interests were noted by board members. It was deemed that none of the interests disclosed have a material commercial and/or financial impact or the HSE. No board members disclosured gifts or hospitality offered by external bodies in the fast twelve months. No board members noted any contractual relationship with the HSE and in board members noted any other conflicts not covered elsewhere

The Executive Management Team (EMT) in addition to the Board are considered to be key management personnel. Overall remuneration, including those that were appointed and resigned during the year is €2.4m (2020: €2.4m). Two members of the EMT are on secondment from other positions. The Chief Cirical Officer is seconded to the HSE from the Mercy Hospital, Cork. The National Lead for Testing and Contact Tracing was seconded from Ernet and Young (EY), without charge to the HSE up to and including the 24th October 2021.

The Board members are in receipt of fees. There is one exception (not in receipt of fees); due to the one person, one salary rule. Other than disclosed in Note 2, all other key management who are in receipt of remuneration comprise of basic pay only.

With the exception of the CEO, other appointed members of the Executive Management Team who are in receipt of remuneration are members of the approved HSE pension schemes (and in the case of the Chief Cirical Officer the Voluntary Hospitals Superannustion Scheme). Their pension entitlements with the HSE do not extend beyond the standard entitlements applicable to these schemes.

Contingent Asset Note 28

As part of the HSE's COVID-19 response, the HSE engaged with various third parties to provide laboratory testing (COVID-19 testing services).

From April 2020 to date, VAT has been charged on some of the COVID-19 testing services provided. The HSE considers these services are exempt from VAT on the basis that the services fail within the scope of modical tests preceived by a medical practitioner but carried out by a third party.

This issue has not been resolved in 2021 and the HSE confininged to be standard rate VAT.

The HSE's view, and that of its advisors, is that the services provided fail within the exemption and that the VAT paid should be recoverable.

The HSE's view, and that of its advisors, is that the services provided fail within the exemption and that the VAT paid should be recoverable.

The HSE's view, and that of its advisors, is that the services provided fail within this exemption and that the VAT paid should be recoverable.

Engagement with the HSE and the appropriate third parties is at an advanced stage and it is expected that this issue will be resolved in 2022.

Approval of Financial The Financial Statements were approved by the Board on 27 May 2022, Statements Note 29